183 related articles for article (PubMed ID: 21726771)
1. A new salicylic acid-derivatized kojic acid vanadyl complex: synthesis, characterization and anti-diabetic therapeutic potential.
Wei Y; Zhang C; Zhao P; Yang X; Wang K
J Inorg Biochem; 2011 Aug; 105(8):1081-5. PubMed ID: 21726771
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, characterization and anti-diabetic therapeutic potential of a new benzyl acid-derivatized kojic acid vanadyl complex.
Wei YB; Yang XD
Biometals; 2012 Dec; 25(6):1261-8. PubMed ID: 23015214
[TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential.
Thompson KH; Liboiron BD; Sun Y; Bellman KD; Setyawati IA; Patrick BO; Karunaratne V; Rawji G; Wheeler J; Sutton K; Bhanot S; Cassidy C; McNeill JH; Yuen VG; Orvig C
J Biol Inorg Chem; 2003 Jan; 8(1-2):66-74. PubMed ID: 12459900
[TBL] [Abstract][Full Text] [Related]
4. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes.
Thompson KH; Chiles J; Yuen VG; Tse J; McNeill JH; Orvig C
J Inorg Biochem; 2004 May; 98(5):683-90. PubMed ID: 15134913
[TBL] [Abstract][Full Text] [Related]
5. The influence of BMOV [bis(maltolato)oxovanadium(IV)] on biochemical and morphological alterations characteristic for streptozotocin-diabetic rat liver Golgi complexes.
Dabroś W; Dziga D; Kordowiak AM
Pol J Pathol; 2002; 53(4):205-13. PubMed ID: 12597338
[TBL] [Abstract][Full Text] [Related]
6. The influence of a new vanadium compound, bis(2,2'-bipyridine)oxovanadium(IV) sulphate on liver golgi complexes from control and streptozotocin-diabetic rats.
Kordowiak AM; Dabroś W; Kajda B
Horm Metab Res; 2002 Oct; 34(10):556-60. PubMed ID: 12439783
[TBL] [Abstract][Full Text] [Related]
7. A new orally active antidiabetic vanadyl complex--bis(alpha-furancarboxylato)oxovanadium(IV).
Xie M; Gao L; Li L; Liu W; Yan S
J Inorg Biochem; 2005 Feb; 99(2):546-51. PubMed ID: 15621288
[TBL] [Abstract][Full Text] [Related]
8. Streptozotocin-induced alterations in rat liver Golgi complexes are ameliorated by BMOV [Bis(maltolato)oxovanadium(IV)] activity.
Kordowiak AM; Dziga D; Dabroś W
Horm Metab Res; 2004 Mar; 36(3):148-54. PubMed ID: 15057667
[TBL] [Abstract][Full Text] [Related]
9. Is the hypoglycemic action of vanadium compounds related to the suppression of feeding?
Huang M; Wu Y; Wang N; Wang Z; Zhao P; Yang X
Biol Trace Elem Res; 2014 Mar; 157(3):242-8. PubMed ID: 24446192
[TBL] [Abstract][Full Text] [Related]
10. Effect of chronic treatment with Bis(maltolato)oxovanadium (IV) in rat model of non-insulin-dependent-diabetes.
Shinde UA; Mehta AA; Goyal RK
Indian J Exp Biol; 2001 Sep; 39(9):864-70. PubMed ID: 11831366
[TBL] [Abstract][Full Text] [Related]
11. Bis(allixinato)oxovanadium(IV) complex is a potent antidiabetic agent: studies on structure-activity relationship for a series of hydroxypyrone-vanadium complexes.
Adachi Y; Yoshida J; Kodera Y; Katoh A; Takada J; Sakurai H
J Med Chem; 2006 Jun; 49(11):3251-6. PubMed ID: 16722643
[TBL] [Abstract][Full Text] [Related]
12. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats.
Niu Y; Liu W; Tian C; Xie M; Gao L; Chen Z; Chen X; Li L
Eur J Pharmacol; 2007 Oct; 572(2-3):213-9. PubMed ID: 17651728
[TBL] [Abstract][Full Text] [Related]
13. The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Zhang SQ; Zhong XY; Chen GH; Lu WL; Zhang Q
J Pharm Pharmacol; 2008 Jan; 60(1):99-105. PubMed ID: 18088510
[TBL] [Abstract][Full Text] [Related]
14. Hypoglycemic effect of macrocyclic binuclear oxovanadium (IV) complex on streptozotocin-induced diabetic rats.
Ramachandran B; Sekar DS; Kandaswamy M; Narayanan V; Subramanian S
Exp Diabesity Res; 2004; 5(2):137-42. PubMed ID: 15203884
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, spectroscopic, structural and thermal characterizations of vanadyl(IV) adenine complex prospective as antidiabetic drug agent.
El-Megharbel SM; Hamza RZ; Refat MS
Spectrochim Acta A Mol Biomol Spectrosc; 2015 Jan; 135():850-64. PubMed ID: 25150436
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
[TBL] [Abstract][Full Text] [Related]
17. Acute and chronic response to vanadium following two methods of streptozotocin-diabetes induction.
Yao J; Battell ML; McNeill JH
Can J Physiol Pharmacol; 1997 Feb; 75(2):83-90. PubMed ID: 9114928
[TBL] [Abstract][Full Text] [Related]
18. Syntheses of vanadyl and zinc(II) complexes of 1-hydroxy-4,5,6-substituted 2(1H)-pyrimidinones and their insulin-mimetic activities.
Yamaguchi M; Wakasugi K; Saito R; Adachi Y; Yoshikawa Y; Sakurai H; Katoh A
J Inorg Biochem; 2006 Feb; 100(2):260-9. PubMed ID: 16387366
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and anti-diabetic activity of new N,N-dimethylphenylenediamine-derivatized nitrilotriacetic acid vanadyl complexes.
Niu X; Yang J; Yang X
J Inorg Biochem; 2017 Dec; 177():291-299. PubMed ID: 28709620
[TBL] [Abstract][Full Text] [Related]
20. Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats.
Reul BA; Amin SS; Buchet JP; Ongemba LN; Crans DC; Brichard SM
Br J Pharmacol; 1999 Jan; 126(2):467-77. PubMed ID: 10077240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]